Patient Reported Outcomes After Radical Cystectomy

Size: px
Start display at page:

Download "Patient Reported Outcomes After Radical Cystectomy"

Transcription

1 Patient Reported Outcomes After Radical Cystectomy Scott M Gilbert, MD, MS, FACS Associate Member GU Oncology & Health Outcomes and Behavior Programs H. Lee Moffitt Cancer Center & Research Institute

2 Disclosures Florida Biomedical Research Program 3BN03 (BCOIS, PI Gilbert) NCI 1-R01CA (BCQOL, PI McMullen) No Industry/Commercial Disclosures

3 What Do We Mean By Success? What defines success? How should we measure it?

4 Some Common Measures of Success Stein et al. J Clin Oncol 2001;19: Grossman et al. N Engl J Med 2003;349: Hu et al. Cancer 2014:120;

5 Usual Suspects Survival (overall, cause-specific) Recurrence Response rate Adverse event/complication Functional outcomes

6 Success Depends On Your Perspective

7 Patient Perspectives and Reports May/Should Dictate Quality Structure Process Outcome How care is organized and where it is provided What is done End results of care

8 Patient Preference Structure Process Outcome How care is organized and where it is provided What is done End results of care Patient Perspective

9 Patient Reported Outcomes (PROs): Definition any report of the status of a patient s health condition that comes directly from the patient without interpretation of the patient s response by a clinician or anyone else. US Food and Drug Administration definition

10 Patient Reported Outcomes (PROs): An Alternative Measure of Success any report of the status of a patient s health condition that comes directly from the patient without interpretation of the patient s response by a clinician or anyone else. Example US Food and Drug Administration definition

11 Why/How Are PROs Important Provide an alternative perspective to clinical and clinician-based outcomes Provide more patient-centered information that may be more relevant Reflect health states/conditions that may not be captured by other outcomes (e.g. symptoms, QOL) Provide information warranting additional investigation/research Adaptable as clinical tools/ques that can help guide care

12 Often Correlate With Hard Outcomes Baseline QOL and QOL deficits have been linked to lower survival in lung, colon and pancreatic cancer Baseline QOL deficits also correlate with poor QOL outcomes post-treatment and are associated with complications Early serious (grade 2-4) complications more likely (16% vs. 6%, p=0.023) among colorectal patients with identified preoperative QOL deficit in COST Trial Bingener J et al. J Gastrointest Surg 2015;19:65-71

13 Provide Different View and More Detail Hubble Telescope New Horizons Probe

14 Current State of Knowledge and Use of Patient-Reported Outcomes/Quality of Life in the Managing Bladder Cancer

15 QOL Declines After Diagnosis/Treatment Reeve et al. J Natl Cancer Inst 2009;101:

16 QOL After Cystectomy Somani BK et al. Urology 2009;74(5):

17 Quality of Life After Cystectomy Adjusted mean BCI scores by treatment group - Mean scores varied by treatment type with cystectomy patients experiencing lower scores than native bladder group - Urinary function scores lowest among continent diversion group - Primarily driven by frequent urine leakage and lack of urinary control (continence) - 54% patients reported urinary leakage every night and 48% reported no urine control or frequent leakage at night Gilbert et al. Cancer 2007;109(9):

18 Quality of Life After Cystectomy Hedgepeth et al. Urology 2010;76:671-6

19 Patient Reported Distress Related to Cystectomy Distress Thermometer - Peak Concerns According to Phase of Recovery after Cystectomy Danilla Wittmann, University of Michigan (unpublished)

20 How Might PROs/QOL Could Be Used More Meaningfully or Impact the Future Care of Cystectomy Patients?

21 QOL Outcomes Drove Uptake of Laparoscopic Colonoscopy Weeks JC et al. JAMA 2002;287(3): Stucky CC et al. Ann Surg Oncol 2011;18:

22 Maybe a Primary Outcome Justifying Robotic Cystectomy? Pilot prspetive RCT comapring robot-assisted lap cystectomy to open cystectomy (NCT ) 40 pts randomized in 1:1 allocation QOL assessed with FACT-VCI at 3,6,9 and 12 months postsurgery No QOL differences noted Messer JC et al. BJU Int 2014;114: Khan MS et al Eur Urol 2015; ahead of print

23 PRO Integration into Care Settings Can Help Manage Symptom Distress RCT b/w symptom/qol assessments vs. assessment with targeted education, communication coaching and outcome tracking in 752 cancer patients Lower symptom distress scores after cancer treatment in intervention group (change in SDS from baseline 1.27 in control group (higher distress) vs in intervention group (lower distress)) Berry DL et al. J Clin Oncol 2014;32:

24 Responding to PROs Can Improve Symptom Management RCT tracking 100 lung cancer patients treated with thoracotomy comparing clinical care team notification of patient reported symptoms to no notification during first month after surgery Intervention (symptom reporting with notification to clinical care team) resulted in lower symptom threshold events (19% vs. 8%) and better symptom control Cleeland CS et al. J Clin Oncol 2011;29:

25 Take Home Messages PROs are an important alternative to traditional outcome measures, and capture both the patient perspective and information that only patients can share Can be used to fill in missing details on how patients do during and after treatment, measure quality, and identify what matters to patients PROs could be integrated into clinical information streams and made actionable (the future?)

MOBILE PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT TO DRIVE ADHERENCE

MOBILE PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT TO DRIVE ADHERENCE MOBILE PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT TO DRIVE ADHERENCE Heather Jim, PhD Moffitt Cancer Center heather.jim@moffitt.org There are no conflicts to disclose LEARNING OBJECTIVES After reading and

More information

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney

More information

Point/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer Pro Trimodality Therapy

Point/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer Pro Trimodality Therapy Point/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer Pro Trimodality Therapy Kimberley S. Mak, MD, MPH Assistant Professor Boston Medical Center Boston University

More information

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Yair Lotan, Robert S. Svatek, Arthur I. Sagalowsky Should We Screen? Prevalence 5 th most common cancer

More information

Early radical cystectomy in NMIBC Marko Babjuk

Early radical cystectomy in NMIBC Marko Babjuk Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,

More information

Laparoscopic Surgery. The Da Vinci Robot. Limits of Laparoscopy. What Robotics Offers. Robotic Urologic Surgery: A New Era in Patient Care

Laparoscopic Surgery. The Da Vinci Robot. Limits of Laparoscopy. What Robotics Offers. Robotic Urologic Surgery: A New Era in Patient Care Laparoscopic Surgery Robotic Urologic Surgery: A New Era in Patient Care Laparoscopic technique was introduced in urologic surgery in the 1990s Benefits: Improved recovery time, decreased morbidity Matthew

More information

ENHANCED RECOVERY AFTER SURGERY (ERAS) PATHWAYS PARESH C. SHAH MD FACS VICE CHAIR OF SURGERY DIRECTOR OF GENERAL SURGERY

ENHANCED RECOVERY AFTER SURGERY (ERAS) PATHWAYS PARESH C. SHAH MD FACS VICE CHAIR OF SURGERY DIRECTOR OF GENERAL SURGERY Department of Surgery Divison of General Surgery ENHANCED RECOVERY AFTER SURGERY (ERAS) PATHWAYS PARESH C. SHAH MD FACS VICE CHAIR OF SURGERY DIRECTOR OF GENERAL SURGERY December 2016 Disclosure Paresh

More information

Elsevier Editorial System(tm) for European Urology Manuscript Draft

Elsevier Editorial System(tm) for European Urology Manuscript Draft Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article

More information

Quality of Life and Satisfaction Among Prostate Cancer Patients Followed in a Dedicated Survivorship Clinic

Quality of Life and Satisfaction Among Prostate Cancer Patients Followed in a Dedicated Survivorship Clinic Original Article Quality of Life and Satisfaction Among Prostate Cancer Patients Followed in a Dedicated Survivorship Clinic Scott M. Gilbert, MD, MS 1,2 ; Rodney L. Dunn, MS 3 ; Daniela Wittmann, PhD

More information

How much colon should be resected?

How much colon should be resected? Colon Cancer Surgical Standard of Care and Operative Techniques Madhulika G. Varma MD Professor and Chief Section of Colorectal Surgery University of California, San Francisco How much colon should be

More information

ROBOTIC VS OPEN RADICAL CYSTECTOMY

ROBOTIC VS OPEN RADICAL CYSTECTOMY ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to

More information

2014 Best Papers in Robotic Cystectomy

2014 Best Papers in Robotic Cystectomy Klinik für Urologie Tübingen 2014 Best Papers in Robotic Cystectomy Dr Allen Sim Introduction! Over 100 publications since introduction of robotic cystectomy in 2003! 30+ publications in 2014 alone Important

More information

Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer

Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Kala Sridhar, MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital GU Medical Oncology Site Group Head Associate Professor, University

More information

A comparison of preliminary oncologic outcome and postoperative complications between patients undergoing either open or robotic radical cystectomy

A comparison of preliminary oncologic outcome and postoperative complications between patients undergoing either open or robotic radical cystectomy ORIGINAL ARTICLE Vol. 42 (4): 663-670, July - August, 2016 doi: 10.1590/S1677-5538.IBJU.2015.0393 A comparison of preliminary oncologic outcome and postoperative complications between patients undergoing

More information

Advanced Pelvic Malignancy: Defining Resectability Be Aggressive. Lloyd A. Mack September 19, 2015

Advanced Pelvic Malignancy: Defining Resectability Be Aggressive. Lloyd A. Mack September 19, 2015 Advanced Pelvic Malignancy: Defining Resectability Be Aggressive Lloyd A. Mack September 19, 2015 CONFLICT OF INTEREST DECLARATION I have no conflicts of interest Advanced Pelvic Malignancies Locally Advanced

More information

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,

More information

Who are Candidates for Laparoscopic or Open Radical Nephrectomy. Arieh Shalhav

Who are Candidates for Laparoscopic or Open Radical Nephrectomy. Arieh Shalhav Who are Candidates for Laparoscopic or Open Radical Nephrectomy Arieh Shalhav Fritz Duda Chair of Urologic Surgery Professor of Surgery and the Comprehensive Cancer Research Center Who are Candidates for

More information

State-of-the-art of surgery for resectable primary tumors

State-of-the-art of surgery for resectable primary tumors Early colorectal cancer State-of-the-art of surgery for resectable primary tumors (Special focus on rectal cancer surgery) Stefan Heinrich & Hauke Lang Department of General, Visceral and University Hospital

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, pancreatic ductal, laparoscopic distal pancreatectomy for, 61 Adrenal cortical carcinoma, laparoscopic adrenalectomy for, 114

More information

Comparative Effectiveness Research of Robotic Surgeries for Cancer Treatment

Comparative Effectiveness Research of Robotic Surgeries for Cancer Treatment Comparative Effectiveness Research of Robotic Surgeries for Cancer Treatment Jim C. Hu MD, MPH Ronald Lynch Professor in Urologic Oncology Director of the LeFrak Center for Robotic Surgery 1 Objectives

More information

Relationship between surgical volume and patient outcomes

Relationship between surgical volume and patient outcomes 7 Relationship between surgical volume and patient outcomes MASSIMILIANO SPALIVIERO AND JAMES A. EASTHAM The authors discuss the inverse relationship between hospital volume of surgical procedures and

More information

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant

More information

Complications in robotic surgery!! Review of the literature! RALP, RAPN and RARC!

Complications in robotic surgery!! Review of the literature! RALP, RAPN and RARC! Complications in robotic surgery Review of the literature RALP, RAPN and RARC Anna Wallerstedt, MD Karolinska University Hospital Stockholm, Sweden Agenda The importance of reporting surgical complications

More information

The patient, your co-pilot in assessing LUTS

The patient, your co-pilot in assessing LUTS The patient, your co-pilot in assessing LUTS Frank Van der Aa Leuven, Belgium This symposium is supported by Astellas Pharma Europe Ltd., including speaker honoraria and production of materials the slides

More information

Exploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies

Exploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies Exploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies Disclosures MDxHealth Scientific Advisor 2 Case Study 54-year-old man referred for a PSA of 7 - Healthy, minimal

More information

Bladder Preservation Strategies for Muscle Invasive Bladder Cancer

Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A. Perez Distinguished Professor of Radiation Oncology Department of Radiation Oncology

More information

Presentation with lymphadenopathy

Presentation with lymphadenopathy Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited

More information

Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic

Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of

More information

Presentation with lymphadenopathy

Presentation with lymphadenopathy Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited

More information

Elevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017

Elevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,

More information

Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery

Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery The Condition: Prostate Cancer Your prostate is a walnut-sized gland that is part of the male reproductive system. The prostate

More information

State-of-the-art: vision on the future. Urology

State-of-the-art: vision on the future. Urology State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures

More information

Predictors of use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: Data from a pilot study of 2414 cases

Predictors of use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: Data from a pilot study of 2414 cases Predictors of use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: Data from a pilot study of 2414 cases 2004-2010 Luke Hounsome 1, Gary Abel 2, Julia Verne 1, David Neal

More information

Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes

Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

HIGH MORTALITY AND POOR SURVIVAL OF MEN WITH PROSTATE CANCER IN RURAL AND REMOTE AUSTRALIA

HIGH MORTALITY AND POOR SURVIVAL OF MEN WITH PROSTATE CANCER IN RURAL AND REMOTE AUSTRALIA HIGH MORTALITY AND POOR SURVIVAL OF MEN WITH PROSTATE CANCER IN RURAL AND REMOTE AUSTRALIA The prostate is a small gland the size of a walnut which produces fluid to protect and lubricate the sperm It

More information

Role of surgery. Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam

Role of surgery. Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Role of surgery Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Surgery and alternative treatments Radical prostatectomy Open Laparoscopic Robot-assisted Temperature

More information

Nihal Mohamed, Ph.D. Michael A. Diefenbach, Ph.D. Mount Sinai School of Medicine Department of Urology & Oncological Sciences, New York

Nihal Mohamed, Ph.D. Michael A. Diefenbach, Ph.D. Mount Sinai School of Medicine Department of Urology & Oncological Sciences, New York Differences between African American and white men in worries and expectations about prostate cancer treatment, need for information, and decisional regret Nihal Mohamed, Ph.D. Michael A. Diefenbach, Ph.D.

More information

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized

More information

Haematuria and Bladder Cancer

Haematuria and Bladder Cancer Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?

More information

Minimal Invasive Approach ro radical cystectomy: Results of the European multicentric study

Minimal Invasive Approach ro radical cystectomy: Results of the European multicentric study Minimal Invasive Approach ro radical cystectomy: Results of the European multicentric study Dr Alexandre Peltier Institut Jules Bordet, Bruxelles (BE) The 9 th Congress of the Lebanese Urology Society

More information

Indications For Partial

Indications For Partial Indications For Partial Nephrectomy Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Endowed Professorship in Urology Department of Urology The University of Texas

More information

Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute

Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute Old and New Radiation for Bladder and Upper Tract Cancers Bridget Koontz Radiation Oncology Duke Cancer Institute Disclosures Janssen funded clinical research BlueEarth Diagnostics advisory board member

More information

Economic Analyses in Clinical Trials

Economic Analyses in Clinical Trials Economic Analyses in Clinical Trials Natasha Leighl (and Nicole Mittmann) Committee on Economic Analysis, NCIC CTG Natasha.Leighl@uhn.on.ca; Nicole.Mittmann@sunnybrook.ca Financial Disclosures Research

More information

Patient Reported Outcomes and Building a Career in Science

Patient Reported Outcomes and Building a Career in Science Patient Reported Outcomes and Building a Career in Science Deborah Watkins Bruner, RN, PhD, FAAN Robert W. Woodruff Professor of Nursing Director, Faculty Mentorship Nell Hodgson Woodruff School of Nursing

More information

Clinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer

Clinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer Clinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer Reference: NHS England B14X08 Information Reader Box (IRB) to be inserted on inside front cover for documents of 6

More information

Open Prostatectomy is Best

Open Prostatectomy is Best Open Prostatectomy is Best William J. Catalona, M.D. The Trifecta Trifecta Cure Continence Potency Northwestern University Feinberg School of Medicine Eastham, J et al, JUrol 179:2207 Continence (Pad Free

More information

12/1/13. What are Pelvic Floor Disorders? What is the Pelvic Floor? Facts. Prevalence of Urinary InconOnence. What s New in Pelvic Floor Disorders?

12/1/13. What are Pelvic Floor Disorders? What is the Pelvic Floor? Facts. Prevalence of Urinary InconOnence. What s New in Pelvic Floor Disorders? What are Pelvic Floor Disorders? Urinary Control Problems - InconOnence or leakage of urine Prolapse of pelvic organs - Vagina, bladder, rectum What s New in Pelvic Floor Disorders? Kimberly Kenton MD,

More information

Bladder replacement in men and women: when and when not? Outline. Continent Diversion History

Bladder replacement in men and women: when and when not? Outline. Continent Diversion History 1 Bladder replacement in men and women: when and when not? Eila C. Skinner, MD Professor of Clinical Urology Keck USC School of Medicine Outline 1) Selection criteria for orthotopic diversion: Tumor-related

More information

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer

More information

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre CHEMO-RADIOTHERAPY FOR BLADDER CANCER Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre AIMS Muscle invasive disease Current Gold-Standard Rationale behind Chemo-Radiotherapy

More information

Update on Haematuria and Bladder Cancer

Update on Haematuria and Bladder Cancer Update on Haematuria and Bladder Cancer Hugh Mostafid FRCS(urol) FEBU Consultant Urologist, Royal Surrey County Hospital and Honorary Senior Lecturer, University of Surrey Guildford None Declarations Recent

More information

Policy #: 370 Latest Review Date: April 2017

Policy #: 370 Latest Review Date: April 2017 Name of Policy: Nerve Graft with Radical Prostatectomy Policy #: 370 Latest Review Date: April 2017 Category: Surgery Policy Grade: B Background/Definitions: As a general rule, benefits are payable under

More information

PSA Screening and Prostate Cancer. Rishi Modh, MD

PSA Screening and Prostate Cancer. Rishi Modh, MD PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University

More information

Department of Urology, Cochin hospital Paris Descartes University

Department of Urology, Cochin hospital Paris Descartes University Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate

More information

Penile Rehabilitation after Radical Prostatectomy

Penile Rehabilitation after Radical Prostatectomy Penile Rehabilitation after Radical Prostatectomy The PRO Position John P. Mulhall MD MSc FECSM FACS Director, Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center

More information

Priestley Lecture Robotics in Ventral Hernia Repair

Priestley Lecture Robotics in Ventral Hernia Repair Priestley Lecture Robotics in Ventral Hernia Repair Mike K. Liang Associate Professor of Surgery McGovern Medical School University of Texas at Houston Houston, Texas Disclosures No Financial Conflict

More information

Urethral catheter removal 3 days after radical retropubic prostatectomy is feasible and desirable

Urethral catheter removal 3 days after radical retropubic prostatectomy is feasible and desirable Urethral catheter 3 days after radical retropubic prostatectomy is feasible and desirable (2002) 5, 291 295 ß 2002 Nature Publishing Group All rights reserved 1365 7852/02 $25.00 www.nature.com/pcan JM

More information

RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management

RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management Nicholas G. Cost, M.D. Assistant Professor, Department of Surgery, Division of Urology University of Colorado Cancer Center Fifteenth

More information

PROSTATE CANCER SCREENING: AN UPDATE

PROSTATE CANCER SCREENING: AN UPDATE PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures

More information

TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?

TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of

More information

Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor

Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor Scott G. Hubosky, MD The Demetrius H. Bagley Jr., MD Associate Professor of Urology Director of Endourology Vice Chair

More information

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Jeffrey M. Holzbeierlein, MD, FACS John W Weigel Professor & Chair Director of Urologic Oncology University of Kansas

More information

Lymph node dissection: how much is enough?

Lymph node dissection: how much is enough? 1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive

More information

Policy #: 370 Latest Review Date: December 2013

Policy #: 370 Latest Review Date: December 2013 Name of Policy: Nerve Graft in Association with Radical Prostatectomy Policy #: 370 Latest Review Date: December 2013 Category: Surgery Policy Grade: B Background/Definitions: As a general rule, benefits

More information

ABLATHERM HIFU THE CANADIAN EXPERIENCE. WILLIAM L. OROVAN McMASTER UNIVERSITY MAPLE LEAF HIFU

ABLATHERM HIFU THE CANADIAN EXPERIENCE. WILLIAM L. OROVAN McMASTER UNIVERSITY MAPLE LEAF HIFU ABLATHERM HIFU THE CANADIAN EXPERIENCE WILLIAM L. OROVAN McMASTER UNIVERSITY MAPLE LEAF HIFU PROCEDURE 1. Spinal Anaesthetic/IV Sedation 2. Right Lateral Decubitus Position 3. Transrectal Probe 4. Catheter

More information

Treatment of localized prostate cancer in elderly patients

Treatment of localized prostate cancer in elderly patients Editorial Treatment of localized prostate cancer in elderly patients Mohammed Haseebuddin, Marc C. Smaldone Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA Correspondence

More information

Curie - davinci connection

Curie - davinci connection Organ sparing treatment in MIBC: Robot assisted laparoscopy & Interstitial Radiotherapy brachytherapy Curie - davinci connection Geert Smits MD PhD FEBU Rijnstate Hospital, Arnhem, NL 010 Geert Smits Intuitive:

More information

Kathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA

Kathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA Kathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA Disclosures Advisory Board and/or Speaker Allergan Medtronic Astellas AUA Guidelines

More information

Ein Leben nach tiefer Rektumresektion: Was erwartet unsere Patienten im Langzeitverlauf?

Ein Leben nach tiefer Rektumresektion: Was erwartet unsere Patienten im Langzeitverlauf? Ein Leben nach tiefer Rektumresektion: Was erwartet unsere Patienten im Langzeitverlauf? Dieter Hahnloser Klinik für Viszeral- und Transplantationschirurgie UniverstätsSpital Zürich Low Rectal Resection

More information

URINARY DIVERSIONS. Winter 2016 Dr P. O Malley

URINARY DIVERSIONS. Winter 2016 Dr P. O Malley URINARY DIVERSIONS Winter 2016 Dr P. O Malley OVERVIEW Who gets diversions? What s involved with cystectomy? What are the different types of diversions? What are the problems with various diversions? How

More information

Detection & Risk Stratification for Early Stage Prostate Cancer

Detection & Risk Stratification for Early Stage Prostate Cancer Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:

More information

Prostate Cancer Dashboard

Prostate Cancer Dashboard Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment

More information

Huang et al. BMC Urology (2015) 15:117 DOI /s

Huang et al. BMC Urology (2015) 15:117 DOI /s Huang et al. BMC Urology (2015) 15:117 DOI 10.1186/s12894-015-0113-7 RESEARCH ARTICLE Quality-of-life outcomes and unmet needs between ileal conduit and orthotopic ileal neobladder after radical cystectomy

More information

How to select the right patient for the right treatment: What role does sexuality play in Pca treatment?

How to select the right patient for the right treatment: What role does sexuality play in Pca treatment? How to select the right patient for the right treatment: What role does sexuality play in Pca treatment? Andrea Salonia, MD, PhD, FECSM Università Vita-Salute San Raffaele Director, URI-Urological Research

More information

Outcomes. Glickman Urological & Kidney Institute

Outcomes. Glickman Urological & Kidney Institute Outcomes 28 Glickman Urological & Kidney Institute Prostate Cryotherapy Cryotherapy has recently been used for treatment of prostate cancer as primary treatment and after failure of radiation treatment.

More information

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS Management of High-Risk Non-Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of

More information

Challenge: the elderly patient with cancer The physical therapists perspective

Challenge: the elderly patient with cancer The physical therapists perspective Challenge: the elderly patient with cancer The physical therapists perspective Aniek Heldens, MSc, PT Christel van Beijsterveld, MSc, PT Department physical therapy, MUMC+ Rehabilitation and functioning,

More information

Life & Bladder Cancer - The Yorkshire Survey

Life & Bladder Cancer - The Yorkshire Survey Life & BC Life & Bladder Cancer - The Yorkshire Survey Prof. James Catto University of Sheffield Prostate Colon Bladder Lung Renal NHL Oral cavity Melanoma Leukaemia Bladder Cancer - Prevalence 400000

More information

Body Image Following Radical Cystectomy and Ileal Neobladder or Conduit in Korean Patients

Body Image Following Radical Cystectomy and Ileal Neobladder or Conduit in Korean Patients www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.3.161 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.3.161&domain=pdf&date_stamp=2014-03-17

More information

3/6/2018 PROSTATE CANCER IN 2018 OBJECTIVE WHAT IS THE PROSTATE? WHAT DOES IT DO? Rahul Mehan, MD

3/6/2018 PROSTATE CANCER IN 2018 OBJECTIVE WHAT IS THE PROSTATE? WHAT DOES IT DO? Rahul Mehan, MD PROSTATE CANCER IN 2018 Rahul Mehan, MD East Valley Urology Center 6116 E Arbor Ave, Bldg 2, Suite 108 Mesa, AZ 85206 rmehan@evucenter.com www.evucenter.com Snapchat: Dr.NoodleKing OBJECTIVE Offer interactive

More information

MEDICAL POLICY SUBJECT: TRANSRECTAL ULTRASOUND (TRUS)

MEDICAL POLICY SUBJECT: TRANSRECTAL ULTRASOUND (TRUS) MEDICAL POLICY SUBJECT: TRANSRECTAL ULTRASOUND 06/16/05, 05/18/06, 03/15/07, 02/21/08 PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under

More information

Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center

Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th

More information

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate Dr. Tareq Salah Ahmed,MD,ESMO Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate 1 st Assiut Urology department conference,marsa Alam 3 rd February 2015 Bladder cancer

More information

ESPEN Congress Madrid 2018

ESPEN Congress Madrid 2018 ESPEN Congress Madrid 2018 The Role Of Obesity In Cancer Survival And Cancer Recurrence Body Composition And Outcomes In Cancer Patients M-C. Gonzalez (BR) The role of obesity in cancer survival and cancer

More information

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy

More information

Pelvic Floor Therapy for the Oncology Patient

Pelvic Floor Therapy for the Oncology Patient Therapy for the Oncology Patient CARINA SIRACUSA, PT, DPT, WCS OHIOHEALTH PELVIC FLOOR PHYSICAL THERAPIST ONCOLOGY REHABILITATION PROGRAM COORDINATOR What does a pelvic floor therapist treat? Muscles Muscles

More information

Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent

Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent Jehonathan H Pinthus MD, Ph.D, FRCSC Associate Professor Department of Surgery/Urology McMaster University Life expectancy Current age

More information

HCC Screening Compliance Module: A Tool for Automated Compliance Monitoring, Clinician Notification, and Efficacy Research

HCC Screening Compliance Module: A Tool for Automated Compliance Monitoring, Clinician Notification, and Efficacy Research SIIM 2017 Scientific Session Quality & Performance Improvement Part 2 Friday, June 2 7:00 am 8:00 am HCC Screening Compliance Module: A Tool for Automated Compliance Monitoring, Clinician Notification,

More information

BPH with persistently elevated PSA 아주대학교김선일

BPH with persistently elevated PSA 아주대학교김선일 BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547

More information

SURGERY, TRANSPLANTATION AND POLYCYSTIC DISEASE. Mr Nick Inston PhD FRCS Consultant Transplant Surgeon Queen Elizabeth Hospital Birmingham

SURGERY, TRANSPLANTATION AND POLYCYSTIC DISEASE. Mr Nick Inston PhD FRCS Consultant Transplant Surgeon Queen Elizabeth Hospital Birmingham SURGERY, TRANSPLANTATION AND POLYCYSTIC DISEASE Mr Nick Inston PhD FRCS Consultant Transplant Surgeon Queen Elizabeth Hospital Birmingham What are polycystic kidneys and livers?! Cystic degenerative condition!

More information

Sentinel Lymph Node Biopsy in Other Tumours: Sentinel Lymph Node Biopsy in Other Tumours. Methodology. Results. Key Questions to Consider

Sentinel Lymph Node Biopsy in Other Tumours: Sentinel Lymph Node Biopsy in Other Tumours. Methodology. Results. Key Questions to Consider Sentinel Lymph Node Biopsy in Other Tumours Dr. Rona Cheifetz Surgical Oncology Update November 24, 2006 Sentinel Lymph Node Biopsy in Other Tumours: An Operation Looking for an Application Dr. Rona Cheifetz

More information

Prostate Cancer Who needs active surveillance?

Prostate Cancer Who needs active surveillance? Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller Prostate Cancer Who needs active surveillance? Klinische und molekulare Charakterisierung des Hoch-Risiko-Prostatakarzinoms.

More information

Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism

Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism Annie Young PhD Professor of Nursing, University of Warwick, UK on behalf of the select-d Collaborative

More information

Prescribing Guidelines for Urinary Tract Infections

Prescribing Guidelines for Urinary Tract Infections Prescribing Guidelines for Urinary Tract Infections Urinary Tract Infections in Children Urinary tract infections (UTIs) are common infections of childhood that may affect any part of the urinary tract,

More information

Debate: Genetics and Genomics should be used ONLY for re-biopsy

Debate: Genetics and Genomics should be used ONLY for re-biopsy Debate: Genetics and Genomics should be used ONLY for re-biopsy Larry Goldenberg, CM, OBC, MD, FRCSC Professor, UBC Dept of Urologic Sciences Director of Development and Supportive Care, Vancouver Prostate

More information

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,

More information

Case Discussions: Prostate Cancer

Case Discussions: Prostate Cancer Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of

More information

Adult cancer survivorship

Adult cancer survivorship Adult cancer survivorship Jennifer M. Jones, PhD Director of Research, Cancer Survivorship Program and Centre for Health Wellness and Cancer Survivorship (ELLICSR) Princess Margaret Cancer Centre, UHN

More information

The role of smoking cessation in clinical oncology: Australian oncologists experiences, preferences and practices

The role of smoking cessation in clinical oncology: Australian oncologists experiences, preferences and practices The role of smoking cessation in clinical oncology: Australian oncologists experiences, preferences and practices Paul C, Day F, Chen T, Martin J, Sitas F, Weber M, Sherwood E, Barbouttis M, Varlow M CINSW

More information